Compare PAR & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | AGMB |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | 62 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.6M | 562.4M |
| IPO Year | 1995 | N/A |
| Metric | PAR | AGMB |
|---|---|---|
| Price | $16.67 | $13.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $33.20 | $32.00 |
| AVG Volume (30 Days) | ★ 1.3M | 98.9K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $455,547,000.00 | N/A |
| Revenue This Year | $9.82 | N/A |
| Revenue Next Year | $11.27 | $17.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.16 | N/A |
| 52 Week Low | $11.59 | $8.75 |
| 52 Week High | $72.15 | $17.45 |
| Indicator | PAR | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 64.12 |
| Support Level | $12.50 | $9.54 |
| Resistance Level | $22.48 | $14.19 |
| Average True Range (ATR) | 0.96 | 1.17 |
| MACD | 0.21 | 0.36 |
| Stochastic Oscillator | 92.84 | 81.52 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.